Clinical Trials on Carcinoma, Squamous Cell of the Head and Neck

Total 6283 results

EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany; GORTEC (Head and Neck Oncology and Radiotherapy...

Active, not recruiting

A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)

Squamous Cell Carcinoma of the Head and Neck

United States, Spain, Korea, Republic of, Taiwan, China, Argentina, France, Japan, Israel, United Kingdom, Belgium, Germany, Portugal, Greece, Italy, Georgia, Australia, Czechia, Brazil, Canada, Austria, Russian Federation, Switzerland and more
Boehringer Ingelheim

Completed

Single Dose Escalation Study of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck

Head and Neck Neoplasms
Ulrich Keilholz
Charite University, Berlin, Germany; AstraZeneca

Completed

Feasibility & Efficacy of Durvalumab+Tremelimumab+RT and Durvalumab+RT in Non-resect. Locally Advanced HPVnegativ HNSCC (DURTRE-RAD)

Squamous Cell Carcinoma of the Head and Neck

Germany
Debiopharm International SA

Completed

Debio 1143-201 Dose-finding and Efficacy Phase I/II Trial

Squamous Cell Carcinoma of the Head and Neck

France, Switzerland
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer

Squamous Cell Carcinoma of the Head and Neck

United States, Italy, Japan, Spain, Taiwan, Korea, Republic of, France, Poland, Russian Federation, Turkey
Hellenic Cooperative Oncology Group
AstraZeneca

Completed

Preoperative Administration of Olaparib With Cisplatin or With Durvalumab or Alone or no Tratment in Patients Who Are Candidates for Surgery of Carcinoma of the Head and Neck. (OPHELIA)

Squamous Cell Carcinoma of the Head and Neck

Greece
International Atomic Energy Agency
Tata Memorial Centre; University of Maryland, College Park; Centro de Lucha contra... and other collaborators

Unknown

Resource Sparing Curative Radiotherapy for Locally Advanced Squamous Cell Cancer of the Head and Neck: The HYPNO Trial (HYPNO)

Squamous Cell Carcinoma of the Head and Neck

India, Argentina, Cuba, Indonesia, Pakistan, Philippines, South Africa, Thailand, Uruguay
Merck KGaA, Darmstadt, Germany

Completed

Cetuximab With Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck in Chinese Subjects (CHANCE)

Squamous Cell Carcinoma of the Head and Neck

China
Beth Israel Medical Center

Completed

Study of Unilateral Neck Irradiation in Patients With SCC of the Head and Neck (Unilateral)

Squamous Cell Carcinoma of the Head and Neck

United States
Krzysztof Misiukiewicz
Sanofi; Icahn School of Medicine at Mount Sinai

Completed

Cabazitaxel - PF Induction Chemotherapy

Squamous Cell Carcinoma of the Head and Neck

United States
Karolinska University Hospital

Unknown

Randomised Phase II, Cetuximab in Combination With 5FU and Cisplatin or Carboplatin Versus Cetuximab in Combination With Paclitaxel and Carboplatin for Treatment of Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck (CETMET)

Squamous Cell Carcinoma of the Head and Neck

Denmark, Sweden
AstraZeneca

Completed

Head and Neck Phase III Iressa Versus Methotrexate Refractory: Iressa Versus Methotrexate (IMEX)

Squamous Cell Carcinoma of the Head and Neck

Croatia, Sweden, United States, Czech Republic, Italy, Russian Federation, South Africa, Spain, United Kingdom, Estonia, Latvia, Lithuania, Norway, Canada, Netherlands, Argentina, Belgium, Greece, Thailand, India, Israel, Malaysia, ... and more
Michael Topf

Recruiting

(89Zr Panitumumab) With PET/CT for Diagnosing Metastases in Patients With Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma | Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck

United States
University of Nebraska

Terminated

Docetaxel and Capecitabine With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Head and Neck Squamous Cell Carcinoma

United States
AIO-Studien-gGmbH
Merck Sharp & Dohme LLC

Not yet recruiting

Head and Neck Carcinoma Clinical Research Platform for Molecular and Blood-based Biomarkers, Treatment and Outcome (HEAT)

Squamous Cell Carcinoma of the Larynx | Squamous Cell Carcinoma of the Oral Cavity | Squamous Cell Carcinoma of the Oropharynx | Squamous Cell Carcinoma of the Hypopharynx

Germany
University of Erlangen-Nürnberg Medical School

Recruiting

De-Intensification of Postoperative Radiotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck (DIREKHT2)

Squamous Cell Carcinoma of the Larynx | Squamous Cell Carcinoma of the Oral Cavity | Squamous Cell Carcinoma of the Oropharynx | Squamous Cell Carcinoma of the Hypopharynx

Germany
AstraZeneca
PRA Health Sciences

Completed

Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Recurrent or Metastatic PD-L1-positive Squamous Cell Carcinoma of the Head and Neck

United States, Belgium, Canada, France, Spain, Korea, Republic of, Hungary, Malaysia, United Kingdom, Taiwan, Germany, Georgia, Israel, Czechia
Andrew Sikora
Advaxis, Inc.

Completed

ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer

Head and Neck Cancer | Squamous Cell Carcinoma of the Head and Neck | HPV Positive Oropharyngeal Squamous Cell Carcinoma

United States
Joseph Califano
Johns Hopkins University; NYU Langone Health; Greater Baltimore Medical Center; San Diego Veterans Healthcare System and other collaborators

Completed

Saliva-based Detection of CD44 (Detect 44)

Squamous Cell Carcinoma of the Head and Neck | Oropharynx Squamous Cell Carcinoma | Oral Cavity Squamous Cell Carcinoma | Squamous Cell Carcinoma of the Oropharynx

United States
Fox Chase Cancer Center

Terminated

Impact of Ribociclib on Head and Neck Squamous Cell Cancer

Squamous Cell Carcinoma of the Head and Neck

United States
Alain Algazi
Genentech, Inc.

Recruiting

Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck

Carcinoma | Cancer | Head and Neck Cancer | Squamous Cell Carcinoma

United States
Amgen

Completed

Radiotherapy Plus Panitumumab Compared to Chemoradiotherapy With Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Cancer | Head and Neck Cancer | Oncology | Squamous Cell Carcinoma
Vaccinex Inc.
Merck Sharp & Dohme LLC

Recruiting

Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (KEYNOTE-B84)

Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)

United States
AstraZeneca

Completed

Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer (EAGLE)

Recurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck SCCHN

United States, France, Italy, Spain, Belgium, Czechia, Romania, Taiwan, Korea, Republic of, Brazil, Hungary, Japan, Russian Federation, Australia, Germany, Israel, Serbia, Bulgaria, Ukraine, Argentina, Poland, Chile, Croatia, Georgia
Danish Head and Neck Cancer Group
International Atomic Energy Agency; Danish Center for Interventional Research...

Terminated

IAEA-HypoX. Accelerated Radiotherapy With or Without Nimorazole in Squamous Cell Carcinoma of the Head and Neck (IAEA-HypoX)

Head and Neck Carcinoma

Egypt, Estonia, Pakistan, Slovenia
Kyunghee Burkitt, DO, PhD

Not yet recruiting

Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCC (HPV)

Squamous Cell Carcinoma of the Larynx | Squamous Cell Carcinoma of the Oral Cavity | HPV-Related Squamous Cell Carcinoma | Squamous Cell Carcinoma of the Oropharynx | Squamous Cell Carcinoma of the Hypopharynx

United States
Emory University
Vaccinex Inc.

Recruiting

VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer

Squamous Cell Carcinoma of the Head and Neck

United States
Cliniques universitaires Saint-Luc- Université...

Recruiting

Patient-derived Xenograft Models of Tumor From Patients With Head and Neck Cancer (UCL-Xenog)

Squamous Cell Carcinoma of the Head and Neck

Belgium
Turku University Hospital

Completed

Reproducibility of Intratumor Distribution of 18F-EF5 in Head and Neck Cancer

Squamous Cell Carcinoma of the Head and Neck

Finland
Washington University School of Medicine

Withdrawn

Effectiveness in Head and Neck Cancer Detection Using Positron Emission Tomography (PET) Insert Device

Squamous Cell Carcinoma of the Head and Neck

United States
Yale University

Withdrawn

Pharmacodynamic Study to Assess the Anti-proliferative Activity of the PARP Inhibitor Olaparib in Patients With HPV Positive and HPV Negative HNSCC

Squamous Cell Carcinoma of the Head and Neck
Providence Health & Services
Bristol-Myers Squibb

Active, not recruiting

Ipilimumab for Head and Neck Cancer Patients

Squamous Cell Carcinoma of the Head and Neck

United States
Celldex Therapeutics

Completed

A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients

Squamous Cell Carcinoma of the Head and Neck

United States
Pfizer
EMD Serono; Astellas Pharma Inc; Nektar Therapeutics

Terminated

Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors

Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Metastatic Castration Resistant Prostate Cancer (mCRPC)

Spain, United States, Poland, Belgium
University of Miami
Regeneron Pharmaceuticals

Withdrawn

Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC)

Head and Neck Squamous Cell Carcinoma | HNSCC | Squamous Cell Carcinoma of the Larynx | Squamous Cell Carcinoma of the Oral Cavity | Squamous Cell Carcinoma of Hypopharynx
Fondazione Policlinico Universitario Agostino Gemelli...

Active, not recruiting

Study of HLA-DR in Cell Cultures Isolated From Primary Squamous Cell Carcinoma

Cancer | Squamous Cell Carcinoma of the Head and Neck

Italy
Washington University School of Medicine

Completed

Determine Tumor Response Using Fluorodeoxyglucose (FDG)- Positron Emission Tomography (PET)/Computed Tomography (CT) Before and After Cetuximab in Patients With Head and Neck Cancer (SCCHN)

Carcinoma, Squamous Cell

United States
Boehringer Ingelheim

Terminated

Dose Escalation of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck or Esophagus

Carcinoma, Squamous Cell
Genmab

Completed

Zalutumumab Pharmacokinetics (PK) in Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Head and Neck Cancer

United Kingdom, Belgium, Slovakia, Hungary
Dana-Farber Cancer Institute
Bristol-Myers Squibb; Altor BioScience; Miltenyi Biomedicine GmbH

Recruiting

CIML NK Cell in Head & Neck Cancer

Squamous Cell Carcinoma of the Head and Neck | Recurrent Head and Neck Squamous Cell Carcinoma

United States
University College, London
AstraZeneca

Withdrawn

Phase I Study of Olaparib With Cisplatin Based Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck (ORCA)

Carcinoma, Squamous Cell
Yale University
Boehringer Ingelheim; National Comprehensive Cancer Network

Recruiting

Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck

Squamous Cell Cancers of the Head and Neck

United States
GlaxoSmithKline
iTeos Therapeutics

Recruiting

Phase 2 Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Neoplasms, Head and Neck

United States, Italy, Spain, Taiwan, Germany, Greece, Korea, Republic of, Romania, Sweden, Turkey, Canada, Argentina, Finland, Brazil, Japan, Poland, Portugal, France, Denmark, Hungary, Norway
UNC Lineberger Comprehensive Cancer Center

Completed

Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN

Head and Neck Cancer | Squamous Cell Carcinoma of the Head and Neck

United States
Incyte Corporation
Bristol-Myers Squibb

Withdrawn

Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310)

Head and Neck Cancer
Genentech, Inc.

Completed

A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck

Head and Neck Cancer

United States, Germany, Spain, France, Australia, Hungary, Belgium, Bulgaria, United Kingdom, Italy, Romania
Milton S. Hershey Medical Center

Withdrawn

Image Guided Intensity Modulated Reirradiation (IG-IMRT) With Cetuximab for Locoregionally Confined Recurrent Head and Neck Squamous Cell Carcinoma

Squamous Cell Cancer of the Head and Neck

United States
Medical University of South Carolina

Recruiting

Pembrolizumab in Combination With Anti-platelet Therapy for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Head and Neck Cancer

United States
University of California, San Diego
Pharmacyclics LLC.

Active, not recruiting

Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC

Head and Neck Cancer | Squamous Cell Carcinoma of the Head and Neck

United States
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (CheckMate 651)

Head and Neck Cancer

Italy, United States, Israel, Japan, Australia, Austria, Brazil, France, Germany, Greece, Ireland, Korea, Republic of, Mexico, Poland, Spain, Switzerland, Taiwan, United Kingdom

Clinical Trials on Carcinoma, Squamous Cell of the Head and Neck

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in El Salvador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations